COVID-19 Vaccine: Serum Institute of India Enters into New Partnership With Bill And Melinda Gates Foundation, Others, to Accelerate Manufacturing & Delivery of 100 Million Doses of Coronavirus Vaccine

Pune, August 7: Serum Institute of India (SII) in Pune announced that it has entered into a new landmark partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of coronavirus vaccines for India and low- income countries.

Also Read | When Will COVID-19 Pandemic End? What’s the Status of Coronavirus Vaccine and Drug? Here Are All FAQs Answered!

According to an ANI update, in another statement, Serum Institute announced that the funding would support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax. These would be available for procurement if they are successful in attaining full licensure and WHO prequalification. COVID-19 Vaccine: Serum Institute Will Make 300-400 Million Doses of 'Covishield' Ready by December 2020, Says Adar Poonawalla.

Serum Institute of India Enters into New Partnership to Accelerate Manufacture & Delivery of 100 Million Doses:

Also Read | Donald Trump Admin Signs Deal for 100 Million Doses of Experimental COVID-19 Vaccine From Sanofi and GlaxoSmithKline at $2.1 Billion

This agreement reportedly excludes major upper-middle and high-income countries, for which Novavax continues to retain rights. Recently, the Drugs Controller General of India (DCGI) gave approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.